ESC Premium Access

Blood pressure control in the general and high risk populations, longitudinal trends.

Congress Session

About the speaker

Associate Professor Jan Bruthans

Thomayer Hospital, Prague (Czechia)
1 presentation
0 follower

5 more presentations in this session

Hypertensive heart disease burden attributable to high salt intake in the United States compared to the European Union and the global status: trends from 1990 to 2019

Speaker: Ms Z. Aryan (Boston, US)

Thumbnail

Effect of the renin angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of 32 randomized controlled trials.

Speaker: Professor M. Banach (Lodz, PL)

Thumbnail

Tissue Doppler E prime velocity and E/E prime predict 19-year cardiovascular mortality in hypertension

Speaker: Doctor A. Ratneswaren (London, GB)

Thumbnail

"Stifflammation" in hypertension is a predictor of future cardiovascular hospitalizations

Speaker: Doctor G. Christopoulou (Dafni-Ymittos, GR)

Thumbnail

Arterial stiffness in adolescence predicts elevated blood pressure in young adulthood: The ALSPAC study

Speaker: Doctor A. Agbaje (Kuopio, FI)

Thumbnail

Access the full session

Congress committee e-posters choice in hypertension

Speakers: Associate Professor J. Bruthans, Ms Z. Aryan, Professor M. Banach, Doctor A. Ratneswaren, Doctor G. Christopoulou...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Other post-COVID consequences: brain, kidneys and skeletal muscles.

27 August 2021

ESC Premium Access

24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk